Clouds Peak New Luminescence: Nephropan has been included in the "2025 KDIGO IgA Nephropathy and IgA Vasculitis Clinical Practice Management Guidelines" as the only recommended first-line therapeutic drug for IgA nephropathy in the guidelines.

According to a message from Yunding Xinyao official WeChat account on the 19th, Nafukang of Yunding Xinyao has been included in the "2025 KDIGO Clinical Practice Guidelines for IgA Nephropathy and IgA Vasculitis" released by the organization for improving the global prognosis of kidney diseases. It is recommended to treat IgA nephropathy patients at risk of progressive decline in renal function with Nafukang for 9 months, clearly establishing its position as first-line therapy. The guidelines also emphasize that a single 9-month course of treatment may not be sufficient to maintain sustained clinical benefits in long-term reduction of proteinuria and stabilization of estimated glomerular filtration rate, therefore extending the treatment time is necessary.